Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Abstract Background Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Inflammation or insulin resistance might be pathological mediators of cardiovascular events in patients with type 2 diabetes. Methods Whether omarigliptin...

Full description

Bibliographic Details
Main Author:	Sachiko Hattori
Format:	Article
Language:	English
Published:	BMC 2020-03-01
Series:	Diabetology & Metabolic Syndrome
Subjects:	Omarigliptin Once-weekly DPP4 inhibitor High-sensitivity C-reactive protein Insulin resistance
Online Access:	http://link.springer.com/article/10.1186/s13098-020-00533-3

Similar Items

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
by: Sachiko Hattori, et al.
Published: (2021-03-01)

Enhanced Extraction Technique of Omarigliptin from Human Plasma—Applied to Biological Samples from Healthy Human Volunteers
by: Shereen Mowaka, et al.
Published: (2020-09-01)

Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
by: Ling Li, et al.
Published: (2021-01-01)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
by: Hiroshi Kasamatsu, et al.
Published: (2021-08-01)

Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A<sub>2A</sub> Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS
by: Bassam M. Ayoub, et al.
Published: (2021-02-01)

Once-a-week versus once-every-3-weeks cisplatin in patients receiving chemoradiation for locally advanced head-and-neck cancer: A survey of practice in India
by: Gautam Goyal, et al.
Published: (2018-01-01)

Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
by: Sachiko Hattori
Published: (2018-12-01)

KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
by: K.V. Andreassen, et al.
Published: (2021-11-01)

IHDIP: a controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients
by: Javier Deira, et al.
Published: (2019-01-01)

Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor
by: Tomoko Okuyama, et al.
Published: (2020-10-01)

Prevention of vertebral fractures in primary osteoporosis with once-weekly teriparatide: A systematic review and meta-analysis of randomized controlled trials
by: Rimesh Pal, et al.
Published: (2021-01-01)

Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly
by: Dorina Cultrera, et al.
Published: (2020-01-01)

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials
by: Philippe Moreau, et al.
Published: (2020-05-01)

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)

Evaluation of the Antidiabetic and Insulin Releasing Effects of <i>A. squamosa</i>, Including Isolation and Characterization of Active Phytochemicals
by: Prawej Ansari, et al.
Published: (2020-10-01)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
by: A Young Sim, et al.
Published: (2021-08-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
by: Junpei Sanada, et al.
Published: (2021-08-01)

Linagliptin use in older individuals with type 2 diabetes
by: Pratley RE
Published: (2014-07-01)

Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications
by: Andrey Santos, et al.
Published: (2021-03-01)

Magnesium supplementation enhances insulin sensitivity and decreases insulin resistance in diabetic rats
by: Hongzhou Liu, et al.
Published: (2020-08-01)

Inflammation and Incretins
by: Amitabh Hatwal
Published: (2012-01-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012-03-01)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
by: Chun-Ting Yang, et al.
Published: (2020-06-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes
by: Frankwich Karen, et al.
Published: (2012-10-01)

Effects of Exenatide Twice Daily and Once Weekly on Weight Loss
by: Patel, Rajal, et al.
Published: (2013)

Antidiabetic effects and mechanisms of action of γ-conglutin from lupin seeds
by: Mrunmai Tapadia, et al.
Published: (2021-12-01)

Ischemic stroke in patients with type 2 diabetes: Relationship between decreased insulin sensitivity and fibrinolysis impairment
by: Jotić Aleksandra, et al.
Published: (2011-01-01)

Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis
by: Lu Yang, et al.
Published: (2018-07-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
by: Woodman OL, et al.
Published: (2019-08-01)

Once-weekly hemodialysis combined with low-protein and low-salt dietary treatment as a favorable therapeutic modality for selected patients with end-stage renal failure: a prospective observational study in Japanese patients
by: Toshiyuki Nakao, et al.
Published: (2018-06-01)

DPP-4 Inhibition in Diabetic Rheumatoid Arthritis Patients
by: Barış Pamuk
Published: (2013-09-01)

Identification of Multiple Pancreatic and Extra-Pancreatic Pathways Underlying the Glucose-Lowering Actions of <i>Acacia arabica</i> Bark in Type-2 Diabetes and Isolation of Active Phytoconstituents
by: Prawej Ansari, et al.
Published: (2021-06-01)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Diabetic nephropathy: newer therapeutic perspectives
by: Krishna C. Keri, et al.
Published: (2018-07-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

Low Frequency Severe-Intensity Interval Training Markedly Alters Respiratory Compensation Point During Incremental Exercise in Untrained Male
by: Hidehiro Nakahara, et al.
Published: (2020-09-01)